HB 962 (see companion bill SB 598) – MarylandStatus: Inactive / Dead
Year Introduced: 2019
Requiring the Maryland Medical Assistance Program, subject to the limitations of the State budget, to provide coverage for any medically appropriate drugs that are approved by the United States Food and Drug Administration for the treatment of hepatitis C, regardless of the fibrosis score, and that are determined to be medically necessary.
Return to Database Search
© 2018-2019 The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.